{
    "nctId": "NCT03634501",
    "briefTitle": "Clinical Study on Anti-tumor Effect Induced by Activated Primary Natural Killer\uff08NK\uff09Cells",
    "officialTitle": "Clinical Study on Anti-tumor Effect Induced by Activated Primary Natural Killer\uff08NK\uff09Cells",
    "overallStatus": "UNKNOWN",
    "conditions": "Lung Cancer, Breast Cancer, Colon Cancer, Pancreatic Cancer, Ovarian Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE1, PHASE2",
    "allocation": "NA",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 200,
    "primaryOutcomeMeasure": "Incidence of toxicity induced by NK infusion",
    "eligibilityCriteria": "Inclusion Criteria:\n\n1. Age from 18 to 75 years (including boundary values);\n2. Diagnosed with histologically and cellularly confirmed cancer of lung, breast, pancreas, ovary, or colon;\n3. At least 8 weeks since any prior systemic therapy to treat the underlying malignancy (standard or investigational);\n4. Life expectancy \\> 6 months, and performance status\uff08KPS\uff09\\> 60 points;\n5. Organ functions meet the following criteria:\n\n   1. Blood bilirubin \\< 2mg/dL,\n   2. Aspartate transaminase\uff08AST\uff09\\<100 IU/L,\n   3. Alanine transaminase\uff08ALT\uff09 \\<100 IU/L,\n   4. Creatinine \\<1.5 mg/dL,\n   5. Urea nitrogen \u2264 25 mg/dL,\n   6. Hemoglobin \u2265 9.0 g/dL,\n   7. White blood cell count\\>3.5\u00d7109/L,\n   8. Neutrophil count \\>1.5x109/L,\n   9. Platelet count \\> 80 \u00d7 109 /L,\n   10. Hematocrit \\>0.20,\n6. No severe infections.\n\nExclusion Criteria:\n\n1. Subjects who take combined systemic steroids within 2 weeks prior to treatment (except inhaled steroids);\n2. Patients who take chemotherapy within 1 month prior to treatment;\n3. Subjects receiving drugs that stimulate the production of bone marrow hematopoietic cells within two weeks prior to treatment;\n4. Patients with T lymphoma and NK cell lymphoma;\n5. Patients with autoimmune diseases, including but not limited to lupus erythematosus, rheumatoid arthritis, etc.;\n6. Seriously uncontrollable infected patients;\n7. Patients who are allergic to the biological agents in this treatment;\n8. Patients with organ transplantation or organ failure;\n9. Subjects with severe cardiovascular disease and severe renal failure;\n10. Patients who are undergoing treatment of immunosuppressive drugs or long-term administration of immunosuppressive drugs after organ transplantation;\n11. Patients with active infection or fever;\n12. Subjects with severe cardiovascular and cerebrovascular diseases, diabetes and renal dysfunction;\n13. Subjects with pregnancy or during the lactating period.",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}